Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New support program aims to ease cancer Patients' transition home from hospital

NCT ID NCT03367247

Symptom relief Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a program called BOLSTER, designed to give extra support to people with gynecologic or gastrointestinal cancers and their caregivers after a hospital stay. The goal was to see if the program was practical and well-liked. 121 adults with complex care needs took part, and the study measured how many agreed to join and how satisfied they were.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

121 people

The number who actually took part.

Started

Apr 2018

Finished

Jul 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Patient inclusion criteria * Adults (≥18 years old); * GYN or GI cancers receiving anti-neoplastic therapy; * Hospitalized, recently hospitalized (i.e. within the first 2 visits after a hospitalization), or recent outpatient placement of tube, line, or drain (e.g. PleurX catheter); * Plan to receive ongoing care at DFCI; * Willingness to be audio taped for the study (for monitoring of study fidelity). * Have complex care needs (e.g. an ostomy, ileostomy, a gastric tube, percutaneous nephrostomy tubes, a PleurX catheter, or need for total parenteral nutrition) Patient exclusion criteria * Unable to read and respond to questions in English; * Cognitive impairment; * Unable to complete the baseline interview; * Plan for immediate hospice referral Caregiver inclusion criteria * Adults (≥18 years old); * Family member or friend of an eligible patient; * Willingness to be audio taped for the study (for monitoring of study fidelity); * Willingness to participate in study visits Caregiver exclusion criteria: * Unable to read and respond to questions in English, * Cognitive impairment * Unable to complete the baseline interview

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastrointestinal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Ascites digestive system cancer digestive system neoplasm female reproductive organ cancer ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastrointestinal cancer Gynecologic cancer

Contacts and locations

Locations

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.